This finding is particularly significant because it suggests that inhibition of HDAC10 may enhance the efficacy of already existing chemotherapeutic agents, providing a combinatorial therapeutic strategy to overcome resistance in CTCL. Here, HDAC10 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.